Background {#Sec1}
==========

Colon cancer is an important cause of cancer-related incidence and mortality and remains a major public health problem worldwide \[[@CR1]\]. The current clinical practice guidelines from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) recommend adjuvant chemotherapy following surgical resection as a standard treatment for patients with stage III colon cancer because of the benefit of chemotherapy in reducing the risk of recurrence and death by eradicating micrometastases \[[@CR2]\].

Several studies have reported that the surgical resection of a primary tumor might induce angiogenesis and proliferation of dormant micrometastases by releasing growth-stimulating factors and triggering immunosuppression that leads to tumor growth \[[@CR3]--[@CR7]\]. Moreover, Harless et al. reported that the effectiveness of adjuvant chemotherapy was inversely proportional to the time from adjuvant chemotherapy initiation to surgical resection \[[@CR8]\]. Therefore, it is a reasonable hypothesis that there may be a time-dependent cut-off point after surgery after which the benefit of adjuvant chemotherapy is not significant because of the failure to eradicate micrometastases. However, the NCCN and ESMO guidelines do not specify an optimal time to initiate adjuvant chemotherapy after surgical resection. Most clinical trials of adjuvant chemotherapy in colon cancer require adjuvant chemotherapy initiation within 6 to 8 weeks after surgical resection \[[@CR9]--[@CR12]\]. Routine preclinical and clinical data suggest that adjuvant chemotherapy in colon cancer should be initiated earlier rather than later, but, in real practice, the initiation of adjuvant chemotherapy in colon cancer is often delayed \[[@CR13], [@CR14]\].

There is no direct and high-quality evidence regarding the importance of the timing of adjuvant chemotherapy in colon cancer. Although two meta-analyses demonstrated that delays in the initiation of adjuvant chemotherapy were detrimental to survival in colorectal cancer \[[@CR15], [@CR16]\], these meta-analyses included both rectal and colon cancer, and it was thus not clear whether the conclusions could be applied to the treatment of colon cancer because of the biological differences between colon cancer and rectal cancer. To date, few retrospective studies evaluated the impact of the timing of adjuvant chemotherapy on survival in colon cancer, and the results were inconsistent \[[@CR17]--[@CR23]\]. Moreover, the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown.

Therefore, this population-based study was conducted to assess the impact of the timing of adjuvant chemotherapy on survival in stage III colon cancer and to assess whether postoperative complications were associated with the timing of adjuvant chemotherapy.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

This study was conducted utilizing the Surveillance, Epidemiology, and End Results (SEER) program and Medicare-linked databases. The SEER program is a comprehensive source of population-based data on patient demographics, tumor characteristics, cancer-related treatments, and causes of death that covers approximately 28% of the population of the United States \[[@CR24]\]. The Medicare database contains individual health insurance claims for approximately 97% of the population aged ≥65 years in the United States and complements the SEER with diagnoses, cancer-related treatments, and outcomes. In the Medicare database, Part A provides health-insurance data about hospitals, skilled-nursing facilities, hospices, and home health care, and Part B provides data about physician and outpatient services \[[@CR25], [@CR26]\]. The SEER-Medicare database was described in our previous study \[[@CR27]\].

The access to the SEER-Medicare database was approved by National Cancer Institute and Information Management Services, Inc. (D6-MEDIC-821), and this study was approved by the Institutional Review Board of the First Hospital of China Medical University.

Study population {#Sec4}
----------------

This study included eligible patients aged ≥66 years from SEER-Medicare database who were diagnosed with primary colon adenocarcinoma from 1992 to 2008 (SEER cancer site codes 18.0, and 18.2 to 18.9). The participating patients fulfilled the American Joint Committee on Cancer (AJCC) staging criteria for stage III colon cancer and underwent primary tumor resection with curative intent within 180 days of diagnosis. The adjuvant chemotherapy regimens were 5-fluorourcil (5-FU)/capecitabine alone or 5-FU/capecitabine plus oxaliplatin (FOLFOX/CapeOX). The non-chemotherapy group included patients with no record of chemotherapy within one year of surgery. The FOLFOX/CapeOX group included patients with any record of 5-FU/capecitabine plus oxaliplatin within 4 weeks of their first chemotherapy dose.

The exclusion criteria were the following: (1) patients who previous non-colon cancer or a diagnosis of non-colon cancer within 1 year of the colon cancer diagnosis, (2) those with incomplete pathological stage entries or diagnostic data, (3) those who received adjuvant chemotherapy only after tumor relapse or metastasis, (4) those who received preoperative neoadjuvant treatments or other adjuvant chemotherapy regimens, (5) those who died within 30 days of diagnosis, and (6) those lacked full coverage from Medicare Parts A and B from 12 months before diagnosis to 9 months after diagnosis or were enrolled in a health maintenance organization.

The National Drug Codes for the drugs and the Health Care Financing Administration Common Procedure Coding System have been previously reported \[[@CR27]\].

Study variables {#Sec5}
---------------

We obtained the patient demographics from the SEER patient entitlement and diagnosis summary file, including gender, age at diagnosis, race, marital status, residence location, household income, education level, and year of diagnosis. The disease characteristics, including primary tumor site (right-side or left-side colon), histologic grade (well differentiated, moderately differentiated, or poorly differentiated/undifferentiated), histologic type (adenocarcinoma, mucinous carcinoma, or signet-ring cell carcinoma), tumor stage, presence of preoperative obstruction or perforation, and number of examined lymph nodes (≥12 or \< 12) were also studied. The tumor stage was assessed based on the seventh edition of the AJCC TNM staging system \[[@CR28], [@CR29]\]. The time to the initiation of adjuvant chemotherapy was defined as the interval between the curative surgery and the administration of the first chemotherapy.

For the evaluation of the comorbidities, we used the Hierarchical Condition Category (HCC) risk score to summarize the health care problems and predict the future health care cost of the population compared with the average Medicare beneficiary (HCC = 1.0), and the HCC risk score was derived from the Medicare inpatient and outpatient claims for various comorbidities within 12 months before the colon cancer diagnosis \[[@CR30]\]. The postoperative complications were identified by assessing the discharge diagnoses within 1 month of surgery.

Statistical analysis {#Sec6}
--------------------

For the descriptive analysis, the categorical variables were compared using χ2 tests and the continuous variables were compared using the Mann-Whitney U tests. In the univariate analysis of survival, Kaplan--Meier survival curves for overall survival (OS) were generated according to the chemotherapy regimen and timing of adjuvant chemotherapy, and these curves were compared using log-rank tests. A spline-based hazard ratio (HR) curve with the corresponding confidence limits was used to evaluate the effect of the continuous covariate of interest (i.e., the timing of adjuvant chemotherapy) on the outcome (OS) \[[@CR31], [@CR32]\]. Multivariate Cox proportional hazards models were used to determine the relationships of multiple survival-related variables with survival.

All statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC, USA), STATA version 12.0 (Stata Corporation, College Station, TX, USA), SPSS version 18.0 (SPSS, Inc., Somers, NY, USA), and R version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). For all analyses, a two-sided *p*-value of less than 0.05 was considered statistically significant.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

A total of 18,491 patients with stage III colon cancer who underwent surgical resection between 1992 and 2008 were identified using the SEER-Medicare database. Among these, 8058 patients received 5-FU or capecitabine alone, 1664 patients received FOLFOX, and 8769 patients did not receive adjuvant chemotherapy. With respect to the timing of adjuvant chemotherapy, 746 patients received adjuvant chemotherapy within 4 weeks after surgery, 6165 patients received adjuvant chemotherapy within 5--8 weeks after surgery, 1883 patients received adjuvant chemotherapy within 9--12 weeks after surgery, 466 patients received adjuvant chemotherapy within 13--16 weeks after surgery, and 462 patients received adjuvant chemotherapy ≥17 weeks after surgery. The patient profiles and disease characteristics are presented in Table [1](#Tab1){ref-type="table"}.Table 1Clinicopathologic features of patients subjected to different chemotherapy regimensNo-chemo5FU/CapecitabineFOLFOX/CapeOXGender Male31243591799 Female56454467865Age at diagnosis, years 66--705541826584 71--7510022422514 76--8017842180419  \> 8054291630147Race White736969091407 Black841592132 Asian24426052 Other31529773Marital status Single+Separated823551125 Married310546201044 Divorced+Widowed45352654443 Other30623352Residence location Big Metro48024219878 Metro or Urban29632853588 Less Urban or Rural1002986198Median household income 1st quartile22031803371 2nd quartile21021976375 3rd quartile20621949393 4th quartile20352029443 Unknown36730182Level of education 1st quartile20642003401 2nd quartile20292015373 3rd quartile21361920400 4th quartile21731819408 Unknown36730182Year of diagnosis 1992--1996183719020 1997--2000167818870 2001--200427393169240 2005--2008251511001424Primary tumor site right-sided colon586751111068 left-sided colon27302809572 unknown17213824Histologic grade Well43242299 Moderate536051691046 Poor+Undifferentiated27562251486 Unknown22121633Histologic type Adenocarcinoma740268111425 Mucinous carcinoma12161140212 Signet-ring cell carcinoma15110727pT category pT117330269 pT2571721150 pT3618558051223 pT4a1040861150 pT4b80036972pN category pN1a33152898500 pN1b28892750554 pN2a15501518357 pN2b1015892253pTNM stage pTNM IIIa673920190 pTNM IIIb623958141132 pTNM IIIc18571324342Preoperative intestinal obstruction No640666481367 Yes23631410297Preoperative intestinal perforation No857679981648 Yes1936016HCC risk score 1st quartile25571811289 2nd quartile16852427539 3rd quartile19722195492 4th quartile25551625344Number of examined lymph node  ≥ 12467442741213  \< 1240953784451Postoperative radiotherapy No869277651639 Yes7729325Timing to AC  ≤ 4 weeks066086 5--8 weeks051181047 9--12 weeks01502381 13--16 weeks036997  ≥ 17 weeks040953 No-chemo876900*Abbreviation: AC* Adjuvant chemotherapy, *HCC* Hierarchical Condition Categories; No-chemo, without adjuvant chemotherapy, *5-FU* 5-fluorouracil, *FOLFOX/CapeOX* 5-FU/capecitabine plus oxaliplatin

Overall comparison of the timing of chemotherapy {#Sec9}
------------------------------------------------

We used a spline-based HR curve to explore the impact of the timing of adjuvant chemotherapy on overall survival in patients with stage III colon cancer. The results indicated that a minimum risk of mortality was achieved at 4 weeks after surgery, and the survival benefits decreased with a delay in the timing of adjuvant chemotherapy of more than 4 weeks (Fig. [1](#Fig1){ref-type="fig"}). Therefore, we used the value of ≤4 weeks as a reference for the survival analysis, and the results of univariate analyses indicated that delayed chemotherapy was significantly associated with worse OS (9--12 weeks: HR = 1.169, 95% confidence interval \[CI\] = 1.019--1.341, *p* = 0.026; 13--16 weeks: HR = 1.237, 95% CI = 1.031--1.483, *p* = 0.022; ≥ 17 weeks: HR = 2.207, 95% CI = 1.870--2.604, *p* \< 0.001). However, chemotherapy that was initiated within 5--8 weeks after surgery did not significantly increase the risk of mortality (HR = 0.982, 95% CI = 0.867--1.113, *p* = 0.780). A Kaplan--Meier survival curve that was stratified by the timing of chemotherapy is presented in Fig. [2](#Fig2){ref-type="fig"}. Multivariate Cox proportional hazards models produced results similar to those of the univariate analyses (5--8 weeks: HR = 1.045, 95% CI = 0.921--1.185, *p* = 0.498; 9--12 weeks: HR = 1.222, 95% CI = 1.063--1.405, *p* = 0.005; 13--16 weeks: HR = 1.252, 95% CI = 1.041--1.505, *p* = 0.017; ≥ 17 weeks: HR = 1.969, 95% CI = 1.663--2.331, p \< 0.001, Table [2](#Tab2){ref-type="table"}). Moreover, the survival benefit of adjuvant chemotherapy was statistically insignificant when adjuvant chemotherapy was initiated ≥21 weeks after resection compared with the non-chemotherapy group (HR = 0.882, 95% CI = 0.763--1.018, *p* = 0.087, Fig. [3](#Fig3){ref-type="fig"}), and chemotherapy initiated ≥25 weeks after surgery did not elicit an OS benefit compared with the non-chemotherapy group (HR = 1.019, 95% CI = 0.863--1.204, *p* = 0.821, Fig. [3](#Fig3){ref-type="fig"}).Fig. 1Splines-based hazard ratio curve for identification of the effect of timing of chemotherapy on overall survival. The solid line presents the relationship (log hazard ratio) between timing of chemotherapy and overall survival, and the dotted line presents the corresponding 95% confidence limitsFig. 2Kaplan--Meier curve of the timing of chemotherapy and overall survival. The *p* value is derived from log-rank test for the overall comparison of overall survival between different timing of chemotherapy and non-chemotherapy groupTable 2Univariate and multivariate Cox proportional hazards analysis of factors influencing the 5-year overall survival for patients who underwent chemotherapyVariablesUnivariate analysisMultivariate analysis^\*^HR95% CI*P*HR95% CI*P*Gender0.136 Male1 Female0.9520.893--1.015Age at diagnosis, years\< 0.001\< 0.001 66--7011 71--751.1571.054--1.2691.1331.030--1.245 76--801.3591.238--1.4921.3301.209--1.463  \> 801.9291.752--2.1231.8341.657--2.029Race\< 0.0010.001 White11 Black1.0390.922--1.1710.9800.864--1.112 Asian0.6250.503--0.7770.6360.511--0.793 Other0.9890.836--1.1690.9610.811--1.139Marital status\< 0.0010.011 Single+Separated11 Married0.8180.723--.9260.8560.755--0.970 Divorced+Widowed0.9940.874--1.1290.9480.833--1.079 Other0.8380.670--1.0470.9050.723--1.133Residence location0.222 Big Metro1 Metro or Urban0.9420.878--1.010 Less Urban or Rural0.9960.901--1.102Median household income0.0230.872 1st quartile11 2nd quartile0.9930.906--1.0881.0420.943--1.152 3rd quartile0.9260.843--1.0161.0000.895--1.119 4th quartile0.8720.795--0.9571.0130.893--1.15 Unknown0.9450.795--1.1231.0560.860--1.298Level of education\< 0.0010.001 1st quartile11 2nd quartile1.1641.061--1.2781.1541.045--1.274 3rd quartile1.1591.055--1.2721.1421.022--1.276 4th quartile1.2621.149--1.3851.2861.130--1.463 Unknown1.1420.960--1.358N/A^a^N/A^a^Year of diagnosis\< 0.001\< 0.001 1992--199611 1997--20000.8630.784--0.9500.8330.756--0.918 2001--20040.8140.748--0.8850.7540.692--0.822 2005--20080.6670.605--0.7370.6090.549--0.675Primary tumor site\< 0.0010.006 right-sided colon11 left-sided colon0.8220.767--0.8800.8910.829--0.957 unknown1.2410.988--1.5591.0340.821--1.302Histologic grade\< 0.001\< 0.001 Well11 Moderate1.1560.987--1.3531.0730.915--1.257 Poor+Undifferentiated1.7481.487--2.0551.3841.174--1.630 Unknown1.2740.991--1.6381.1200.869--1.445Histologic type\< 0.0010.101 Adenocarcinoma11 Mucinous carcinoma1.1231.026--1.2291.0240.934--1.123 Signet-ring cell carcinoma1.8931.503--2.3841.2891.019--1.632pT category\< 0.001\< 0.001 pT111 pT21.0710.824--1.3911.0190.783--1.325 pT32.0251.616--2.5361.5941.269--2.002 pT4a2.982.348--3.7822.2051.732--2.806 pT4b5.4594.253--7.0083.4042.636--4.395pN category\< 0.001\< 0.001 pN1a11 pN1b1.3741.263--1.4951.3051.199--1.420 pN2a1.8441.682--2.0211.6751.526--1.838 pN2b3.2152.920--3.5412.8742.595--3.183Preoperative intestinal obstruction\< 0.001\< 0.001 No11 Yes1.4251.319--1.5401.2461.152--1.349Preoperative intestinal perforation\< 0.0010.001 No11 Yes2.2841.723--3.0281.6281.223--2.168HCC risk score\< 0.001\< 0.001 1st quartile11 2nd quartile0.9500.865--1.0431.1611.053--1.280 3rd quartile1.1091.010--1.2171.3471.223--1.483 4th quartile1.4471.315--1.5931.6441.489--1.815Number of examined lymph node0.003\< 0.001  ≥ 1211  \< 121.1021.034--1.1751.2951.209--1.387Postoperative radiotherapy\< 0.001\< 0.001 No11 Yes1.6201.391--1.8871.3231.133--1.545Timing to AC\< 0.001\< 0.001  ≤ 4 weeks11 5--8 weeks0.9820.867--1.1131.0450.921--1.185 9--12 weeks1.1691.019--1.3411.2221.063--1.405 13--16 weeks1.2371.031--1.4831.2521.041--1.505  ≥ 17 weeks2.2071.870--2.6041.9691.663--2.331*Abbreviation*: *HR* Hazard ratio, *CI* Confidence interval, *HCC* Hierarchical Condition Categories, *AC* Adjuvant chemotherapy^\*^Only variables with a *p* \< 0.05 in the univariate analysis were included in the multivariate analysis^a^unavailable because of colinearity with the variable of Median household incomeFig. 3Hazard ratio plot for the relationship between timing of chemotherapy and overall survival compared with the non-chemotherapy group

Comparison of the timing of FOLFOX/CapeOX chemotherapy {#Sec10}
------------------------------------------------------

Our results indicated that the survival benefit from FOLFOX/CapeOX chemotherapy was more evident than that from 5-FU alone in patients with stage III colon cancer (HR = 0.615, 95% CI = 0.555--0.683, *p* \< 0.001, Fig. [4](#Fig4){ref-type="fig"}), although both chemotherapy regimens significantly improved the OS (p \< 0.001) compared with the non-chemotherapy group. Therefore, the relationship between the timing of FOLFOX/CapeOX chemotherapy and OS was further evaluated. The results of the multivariate analysis indicated that FOLFOX/CapeOX chemotherapy that was initiated within 5--8 weeks did not increase the risk of mortality compared with FOLFOX/CapeOX chemotherapy that was initiated ≤4 weeks after surgery (HR = 1.009, 95% CI = 0.619--1.644, *p* = 0.971, Table [3](#Tab3){ref-type="table"}). However, FOLFOX/CapeOX chemotherapy initiated within 9--12, 13--16, and ≥17 weeks tended to produce worse OS (9--12 weeks: HR = 1.640, 95% CI = 0.990--2.717, *p* = 0.055; 13--16 weeks: HR = 1.422, 95% CI = 0.788--2.566, *p* = 0.243; ≥ 17 weeks: HR = 2.482, 95% CI = 1.354--4.549, *p* = 0.003, Table [3](#Tab3){ref-type="table"}). Indeed, the spline-based HR curve for FOLFOX/CapeOX chemotherapy indicated that the survival benefit of FOLFOX/CapeOX chemotherapy was not statistically significant when it was initiated at ≥19 weeks compared with the non-chemotherapy group (HR = 0.672, 95% CI = 0.441--1.024, *p* = 0.064, Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Kaplan--Meier curve of chemotherapy regimen and overall survival. The p value is derived from log-rank test for the overall comparison of overall survival between different chemotherapy regimens and non-chemotherapy groupTable 3Univariate and multivariate Cox proportional hazards analysis of factors influencing 5-year overall survival for patients who underwent FOLFOX/CapeOX chemotherapyVariablesUnivariate analysisMultivariate analysis^\*^HR95% CI*P*HR95% CI*P*Gender0.092 Male1 Female0.8450.695--1.028Age at diagnosis, years0.0030.007 66--7011 71--751.1220.872--1.4431.1490.888--1.486 76--801.2860.994--1.6651.2930.991--1.688  \> 801.8121.305--2.5171.8161.285--2.566Race0.206 White1 Black1.0280.719--1.469 Asian1.1560.677--1.972 Other0.5020.259--0.973Marital status0.167 Single+Separated1 Married1.0360.696--1.543 Divorced+Widowed1.3180.869--1.999 Other1.0660.540--2.104Residence location0.329 Big Metro1 Metro or Urban1.0710.865--1.327 Less Urban or Rural1.2520.929--1.686Median household income0.0070.497 1st quartile11 2nd quartile0.9620.733--1.2611.0210.755--1.380 3rd quartile0.7450.561--0.9890.8140.575--1.152 4th quartile0.6200.465--0.8260.7920.529--1.186 Unknown0.8000.496--1.2910.9470.514--1.743Level of education0.0060.263 1st quartile11 2nd quartile1.5241.117--2.0791.3710.979--1.920 3rd quartile1.5521.147--2.1001.3790.960--1.982 4th quartile1.7441.298--2.3431.2890.854--1.947 Unknown1.4170.863--2.327N/A^a^N/A^a^Year of diagnosis0.398 2001--20041 2005--20080. 8970.697--1.154Primary tumor site0.150 right-sided colon1 left-sided colon0.8780.711--1.084 unknown1.6020.824--3.114Histologic grade\< 0.0010.022 Well11 Moderate1.1700.724--1.8921.0150.623--1.653 Poor+Undifferentiated1.9731.211--3.2151.4070.856--2.315 Unknown1.3760.598--3.1650.9870.422--2.309Histologic type0.0080.148 Adenocarcinoma11 Mucinous carcinoma1.4911.146--1.9401.3060.997--1.712 Signet-ring cell carcinoma1.4670.728--2.9591.1470.556--2.366pT category\< 0.001\< 0.001 pT111 pT21.3740.499--3.7801.4720.531--4.080 pT33.6451.506--8.8232.7301.118--6.667 pT4a6.2212.494--15.5215.0772.014--12.801 pT4b7.1652.766--18.5594.3501.656--11.424pN category\< 0.001\< 0.001 pN1a11 pN1b1.5811.172--2.1321.4751.090--1.996 pN2a2.3011.691--3.1321.9701.440--2.696 pN2b4.3103.195--5.8143.4082.497--4.650Preoperative intestinal obstruction\< 0.0010.055 No11 Yes1.6801.340--2.1061.2580.995--1.590Preoperative intestinal perforation0. 165 No1 Yes1.7700.790--3.966HCC risk score\< 0.001\< 0.001 1st quartile11 2nd quartile0.9360.683--1.2831.1290.816--1.561 3rd quartile1.0330.754--1.4151.2730.918--1.765 4th quartile1.9941.469--2.7052.1971.592--3.033Number of examined lymph node0.382  ≥ 121  \< 120.9060.727--1.130Postoperative radiotherapy0.055 No1 Yes1.8500.988--3.467Timing to AC\< 0.001\< 0.001  ≤ 4 weeks11 5--8 weeks1.0280.635--1.6631.0090.619--1.6440.971 9--12 weeks1.6651.012--2.7391.6400.990--2.7170.055 13--16 weeks1.6710.935--2.9881.4220.788--2.5660.243  ≥ 17 weeks3.1441.731--5.7102.4821.354--4.5490.003*Abbreviation FOLFOX/CapeOX* 5-FU/capecitabine plus oxaliplatin, *HR* Hazard ratio, *CI* Confidence interval, *HCC* Hierarchical Condition Categories, *AC* Adjuvant chemotherapy^\*^Only variables with a *p* \< 0.05 in the univariate analysis were included in the multivariate analysis^a^unavailable because of colinearity with the variable of Median household incomeFig. 5Hazard ratio plot for the relationship between timing of FOLFOX/CapeOX chemotherapy and overall survival compared with the non-chemotherapy group

Postoperative complications and the timing of chemotherapy {#Sec11}
----------------------------------------------------------

We examined the correlation of postoperative complications with the delayed initiation of adjuvant chemotherapy. The results indicated that patients with postoperative complications had a significantly higher risk of delayed adjuvant chemotherapy (*p* \< 0.05; Fig. [6](#Fig6){ref-type="fig"}). Among the postoperative complications, cardiac arrest (19.50 vs. 8.22 weeks; Δ = 11.28 weeks), ostomy infection (14.60 vs. 8.22 weeks; Δ = 6.38 weeks), shock (13.69 vs. 8.18 weeks; Δ = 5.51 weeks), and septicemia (12.02 vs. 8.13 weeks; Δ = 3.89 weeks) had strong influences on chemotherapy delay with a delay of approximately 4--11 weeks. Additionally, disruption of the operation wound (Δ = 3.11 weeks), peritonitis (Δ = 3.07 weeks), fistula of the gastrointestinal tract (Δ = 2.97 weeks), acute renal failure (Δ = 3.34 weeks), postoperative infection (Δ = 2.85 weeks), intestinal perforation (Δ = 2.02 weeks), acute myocardial infarction (Δ = 1.88 weeks), and stroke (Δ = 1.96 weeks) could result in delays in the initiation of adjuvant chemotherapy of approximately 2--3 weeks. In turn, hemorrhage, pneumonia, urinary infection, pulmonary embolism, respiratory disease, gastrointestinal disorder, anemia, vein disease, gastrointestinal disease, nausea and vomiting, and obstruction had relatively weak impacts on the chemotherapy delay (a delay of approximately 0.5--1.5 weeks), although the differences were significant.Fig. 6Association between postoperative complications and timing of adjuvant chemotherapy (AC) after surgical resection. Orange color bars present the timing of AC among patients with postoperative complications. Blue color bars present the timing of AC among patients without postoperative complications. "\*\*" present a significant difference with *p* value \< 0.01

Discussion {#Sec12}
==========

There is no evidence about the optimal time to initiate adjuvant chemotherapy after surgical resection, or whether there is an ideal timing for adjuvant therapy after which treatment benefit decreases. This population-based study based on the SEER-Medicare databases was conducted to evaluate the relationship between the timing of adjuvant chemotherapy and survival in stage III colon cancer. The results indicated that adjuvant chemotherapy that was initiated within 5--8 weeks after surgery did not increase the risk of mortality compared with chemotherapy initiated at ≤4 weeks after surgery, and the initiation of adjuvant chemotherapy within 8 weeks after surgery was thus feasible. However, adjuvant chemotherapy after 8 weeks of surgery was significantly associated with worse OS. The survival benefit of adjuvant chemotherapy became statistically insignificant when chemotherapy was initiated after 21 weeks compared with the non-chemotherapy group, thus, adjuvant chemotherapy might be still useful even with a delay of approximately 5 months (Fig. [3](#Fig3){ref-type="fig"}). Our results indicated that the survival benefits of the FOLFOX/CapeOX chemotherapy regimen within 5--8 weeks and ≤4 weeks were similar, and chemotherapy initiated ≥19 weeks did not have a significant OS benefit compared with the non-chemotherapy group.

The favorable effect of adjuvant chemotherapy on survival primarily involves the eradication of residual disease and micrometastases. However, the relationship between the timing of adjuvant chemotherapy and survival is unclear. Several studies reported that primary tumor removal could accelerate angiogenesis and growth of residual disease and micrometastases by releasing growth-stimulating factors and promoting immunosuppression \[[@CR3]--[@CR7]\]; thus, a delay in adjuvant chemotherapy might favor tumor angiogenesis and growth, and a long delay could lead to tumor recurrence or metastasis and a consequent failure to achieve the curative potential of adjuvant chemotherapy. Furthermore, Goldie et al. suggested that the drug sensitivity of a tumor was related to the spontaneous mutation rate toward phenotypic drug resistance, which was a function of time \[[@CR33]\]. Moreover, the mathematical model by Harless et al. demonstrated that the effectiveness of chemotherapy was inversely proportional to the tumor burden that had to be eradicated, which, in turn, was a function of the time of the initiation of chemotherapy after surgery \[[@CR8]\]. Therefore, the survival benefit of adjuvant chemotherapy was time-dependent. Studies have also reported that delayed chemotherapy might reflect poor patient and disease characteristics and increase comorbidity, which would be associated with poor prognoses \[[@CR13], [@CR34]\].

Our spline-based HR model revealed that the efficacies of adjuvant chemotherapy within 5--8 weeks and ≤4 weeks were similar, although the minimum risk of mortality was achieved at 4 weeks after surgery. Bos et al. demonstrated that adjuvant chemotherapy within 5--6 weeks or 7--8 weeks after surgery did not decrease OS compared to the initiation of chemotherapy within 4 weeks, and the start of chemotherapy 8 weeks after surgery was associated with a decreased OS \[[@CR35]\]. In clinical practice, it is important to note that the toxicity of chemotherapy may be maximized due to poor immune and performance statuses after surgery, and thus, initiating chemotherapy early may cause severe chemotherapy-related adverse events and even death \[[@CR36]\]. Therefore, an additional survival benefit of excess-early adjuvant chemotherapy may be difficult to detect because of the severe adverse events caused by chemotherapy. The initiation of adjuvant chemotherapy within 8 weeks after surgery was feasible. However, adjuvant chemotherapy that was initiated ≥21 weeks after surgery did not have a significant survival OS benefit compared with the non-chemotherapy group, and conversely, this delay may cause additional chemotherapy-related adverse events. Further studies are needed to explore the optimal timing for adjuvant chemotherapy, for example, identifying the time at which the survival benefit from chemotherapy maximally outweighs the risks of chemotherapy-related adverse events and death.

Several studies reported that patient and disease characteristics, including older age, low income, and high comorbidity, were associated with delayed adjuvant chemotherapy \[[@CR13], [@CR34]\]. Cheung et al. reported that the determinants of delayed adjuvant chemotherapy might be primarily influenced by their relationships with the postoperative complications that ultimately resulted in chemotherapy delay, and these complications seemed to be a more important driver for chemotherapy delay \[[@CR37]\]. Therefore, the relationship between postoperative complications and delayed adjuvant chemotherapy was evaluated, and the results indicated that patients with postoperative complications had a significantly higher risk of delayed adjuvant chemotherapy (*p* \< 0.05). Specifically, cardiac arrest, ostomy infection, shock, and septicemia had strong influences on delayed chemotherapy and caused delays of 4--11 weeks. Moreover, disruption of the operation wound, peritonitis, fistula of the gastrointestinal tract, acute renal failure, postoperative infection, intestinal perforation, acute myocardial infarction, and stroke could cause delays of 2--3 weeks. These results were expected because patients with severe postoperative complications were likely to require more time for recovery. Therefore, multidisciplinary treatment strategies are needed to reduce postoperative complications and promote timely adjuvant chemotherapy.

This study has limitations. First, this was a retrospective SEER-Medicare study, and thus the potential for confounding based on patient selection could not be completely eliminated. Second, the data on the patient/disease characteristics and treatments were obtained from a fee-for-service insurance database. Some clinical variables were not available, and the presence of other important confounding factors could not be discarded. Third, the use of adjuvant chemotherapy may decrease in older patients mainly because older patients are more likely to have high comorbidity and poor performance statuses, and oncologists may be less willing to use adjuvant chemotherapy \[[@CR38], [@CR39]\]. In our study, the results demonstrated that the use of adjuvant chemotherapy was common in older patients with stage III colon cancer (9722/18,491, 52.6%), and adjuvant chemotherapy significantly improved the prognoses compared with the non-chemotherapy group. Additionally, several studies have also demonstrated that older patients with stage III colon cancer gain a significant survival benefit from adjuvant chemotherapy \[[@CR40]--[@CR43]\]. Therefore, further large-scale, high-quality studies are needed to evaluate the interactions of age and the timing of adjuvant chemotherapy with survival in stage III colon cancer. Fourth, disease-free survival was also an appropriate measure for assessing the survival benefit of adjuvant chemotherapy; however, disease-free survival could not be evaluated because the data on disease-free survival was not available in the SEER-Medicare database. Further studies are required to investigate the impact of the timing of adjuvant chemotherapy on disease-free survival. Moreover, it was not feasible to conduct a randomized controlled trial to specifically address the impact of the timing of adjuvant chemotherapy on survival in colon cancer. Thus, larger-scale and well-designed retrospective studies are needed to explore the optimal timing of adjuvant chemotherapy after surgical resection.

Conclusions {#Sec13}
===========

The survival benefits of adjuvant chemotherapy within 5--8 weeks and ≤4 weeks were similar, and thus, initiation of adjuvant chemotherapy within 8 weeks in patients with stage III colon cancer was feasible. Adjuvant chemotherapy 8 weeks after surgical resection was significantly associated with worse OS. However, adjuvant chemotherapy might still be useful even with a delay of approximately 5 months, although the survival benefit was reduced. Additionally, postoperative complications were significantly associated with the delayed initiation of adjuvant chemotherapy in patients with stage III colon cancer.
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